1Hojo Y, Ikeda U, Takahashi M, et al. Matrix metalloproteinase-1 expression by interaction between monocytes and vascular endothelial cells [J].J Mol Cell Cardiol, 2000, 32(8): 1 459-1 468.
2Du-Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity [J]. Immunol Res, 2004, 30(3): 261-277.
3Sjowall C, Wettero J. Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins [J]. Clin Chim Acta, 2007, 378(1-2) : 13-23.
4Marnell L, Mold C, Du-Clos TW. C-reactive protein: ligands, receptors and role in inflammation [J]. Clin Immunol, 2005, 117 (2) : 104-111.
5Williams RC Jr, Harmon ME, Burlingame R, et al. Studies of serum C-reactive protein in systemic lupus erythematosus [J]. J Rheumatol, 2005, 32(3): 454-461.
6Agrawal A, Shrive AK, Greenhough TJ, et al. Topology and structure of the C1q-binding site on C-reactive protein [J]. J Immunol, 2001, 166(6): 3 998-4 004.
7Baek JE, Chang JW, Min WK, et al. Serum high-sensitivity C- reactive protein is not increased in patients with IgA nephropathy [J]. Nephron Clin Pract, 2008, 108(1): c35-c40.
8Sabatine MS,Morrow DA,Jablonski KA,et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease [J]. Circulation, 2007, 115(12): 1 528-1 536.
9Soinio M, Marniemi J, Laakso M, et al. High-sensltlvity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study [J]. Diabetes Care, 2006, 29(2): 329-333.
10Villacorta H, Masetto AC, Mesqulta ET. C-reactive protein: an inflammatory marker with prognostic value in patients with decompensated heart failure [J]. Arq Bras Cardiol, 2007, 88(5): 585-589.
